Targeted removal of migratory tumor cells by functionalized magnetic nanoparticles impedes metastasis and tumor progression

Nanomedicine

Volumn 6, Issue 1, 2011, Pages 69-78

  Scarberry, Kenneth E ^a   Mezencev, Roman ^a   McDonald, John F ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

magnetic filtration; magnetic nanoparticles; metastasis; metastatic disease; ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EPHRIN A2 RECEPTOR; EPHRIN RECEPTOR; GLYCYLGLYCYLGLYCYLGLYCYLTYROSYLSERYLALANYLTYROSYLPROLYLASPARTYLSERYLVALYLPROLYLMETHIONYLMETHIONYLSERYLLYSINE; MAGNETIC NANOPARTICLE; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TARGETING; FEMALE; METASTASIS; MIGRATION INHIBITION; MOUSE; NONHUMAN; OVARY CARCINOMA; PARACENTESIS; PERITONEAL FLUID; PRIORITY JOURNAL;

ANIMALS; EPHRIN-A1; FEMALE; HUMANS; MAGNETICS; MICE; MICE, INBRED C57BL; NANOMEDICINE; NANOPARTICLES; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RECEPTOR, EPHA2;

EID: 78650674462     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.103     Document Type: Article

References (39)

1. Chambers AF, Groom AC, MacDonald IC: Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2(8), 563-572 (2002).
2. Aragon-Ching JB, Zujewski JA: CNS metastasis: an old problem in a new guise. Clin. Cancer Res. 13(6), 1644-1647 (2007).
3. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J. Clin. Oncol. 22(14), 2865-2872 (2004).
4. Roodman GD: Mechanisms of bone metastasis. N. Engl. J. Med. 350(16), 1655-1664 (2004).
5. Herzog TJ, Pothuri B: Ovarian cancer: a focus on management of recurrent disease. Nat. Clin. Pract. Oncol. 3(11), 604-611 (2006).
6. Koolpe M, Dail M, Pasquale EB: An ephrin mimetic peptide that selectively targets the epha2 receptor. J. Biol. Chem. 277(49), 46974-46979 (2002).
7. Scarberry KE, Dickerson EB, McDonald JF, Zhang ZJ: Magnetic nanoparticle- peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J. Am. Chem. Soc. 130(31), 10258-10262 (2008).
8. Zhang L, Yang N, Garcia JRC et al.: Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am. J. Pathol. 161(6), 2295-2309 (2002).
9. Demicheli R, Retsky MW, Hrushesky WJM, Baum M: Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat. Clin. Pract. Oncol. 4(12), 699-710 (2007).
10. Savage P, Stebbing J, Bower M, Crook T: Why does cytotoxic chemotherapy cure only some cancers? Nat. Clin. Pract. Oncol. 6(1), 43-52 (2009).
11. Meads MB, Gatenby RA, Dalton WS: Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9(9), 665-674 (2009).
12. Di Fiore F, Van Cutsem E: Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract. Res. Clin. Gastroenterol. 23(1), 113-124 (2009).
13. Widder KJ, Senyei AE, Scarpelli DG: Magnetic microspheres: a model system for site specifc drug delivery in vivo. Proc. Soc. Exp. Biol. Med. 158(2), 141-146 (1978).
14. Mahmoudi M, Simchi A, Imani M et al.: A new approach for the in vitro identifcation of the cytotoxicity of superparamagnetic iron oxide nanoparticles. Colloids Surf. B Biointerfaces 75, 300-309 (2010).
15. Binhi V: Do naturally occurring magnetic nanoparticles in the human body mediate increased risk of childhood leukaemia with EMF exposure. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 84(7), 569-579 (2008).
16. Sadauskas E, Danscher G, Stoltenberg M, Vogel U, Larsen A, Wallin H: Protracted elimination of gold nanoparticles from mouse liver. Nanomedicine 5, 162-169 (2009).
17. Fent GM, Casteel SW, Kim DY et al.: Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine. Nanomedicine 5, 128-135 (2009).
18. Scarberry KE, Dickerson EB, Zhang ZJ, Benigno BB, McDonald JF: Selective removal of ovarian cancer cells from human ascites fuid using magnetic nanoparticles. Nanomedicine 6(3), 399-408 (2010).
19. Liu C, Zou B, Rondinone AJ, Zhang ZJ: Chemical control of superparamagnetic properties of magnesium and cobalt spinel ferrite nanoparticles through atomic level magnetic couplings. J. Am. Chem. Soc. 122(26), 6263-6267 (2000).
20. Fields GB, Noble RL: Solid-phase peptide synthesis utilizing 9-fuorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35(3), 161-214 (1990).
21. Stehle JR, Willingham MC, Lin K, Cui Z: A non-terminal method for frequent collection of mouse circulating proteins by peritoneal lavage. Anal. Biochem. 349(1), 162-164 (2006).
22. Szczesny G, Veihelmann A, Massberg S, Nolte D, Messmer K: Long-term anaesthesia using inhalatory isofurane in different strains of mice-the haemodynamic effects. Lab. Anim. 38(1), 64-69 (2004).
23. th Edition). Academic Press, Orlando, FL, USA (1996).
24. Roby KF, Taylor CC, Sweetwood JP et al.: Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21(4), 585-591 (2000).
25. Hoskins WJ: Prospective on ovarian cancer: why prevent? J. Cell. Biochem. (Suppl. 23), 189-199 (1995).
26. Chien JR, Aletti G, Bell DA, Keeney GL, Shridhar V, Hartmann LC: Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J. Cell. Biochem. 102, 1117-1129 (2007).
27. Tian X, Song S, Wu J, Meng L, Dong Z, Shou C: Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell mgc803. Biochem. Biophys. Res. Commun. 286, 505-512 (2001).
28. Herold-Mende C, Steiner HH, Andi T et al.: Expression and functional signifcance of vascular endothelial growth factor receptors in human tumor cells. Lab. Invest. 79, 1573-1582 (1999). (Pubitemid 30013922)
29. Dias S, Hattori K, Zhu Z et al.: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106, 511-521 (2000).
30. Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP: Secretion of vascular endothelial growth factor in ovarian cancer. Eur. J. Gynaecol. Oncol. 20, 177-181 (1999).
31. Thaker PH, Deavers M, Celestino J et al.: Epha2 expression is associated with aggressive features in ovarian carcinoma. Clin. Cancer Res. 10, 5145-5150 (2004).
32. Pazdur R: End points for assessing drug activity in clinical trials. Oncologist 13(Suppl. 2), 19-21 (2008).
33. Di Leo A, Bleiberg H, Buyse M: Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported Phase III trials in colorectal and breast cancer. J. Clin. Oncol. 21(10), 2045-2047 (2003).
34. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50(3), 163-170 (1966).
35. Iglewicz B, Hoaglin DC: How to detect and handle outliers. American Society for Quality Control, 16 (1993).
36. Jemal A, Siegel R, Ward E et al.: Cancer statistics. CA Cancer J. Clin. 58(2), 71-96 (2008).
37. Alvero AB, Chen R, Fu H et al.: Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. Cell Cycle 8(1), 158-166 (2009).
38. Smith EM, Jayson GC: The current and future management of malignant ascites. Clin. Oncol. (R. Coll. Radiol). 15(2), 59-72 (2003).
39. Roberts PC, Mottillo EP, Baxa AC et al.: Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model. Neoplasia 7(10), 944-956 (2005).